Give more people weight-loss jabs on the NHS, say MPs

• NHS weight-loss drug access targets are insufficient—MPs argue the current plan to provide Mounjaro to only 6% of eligible patients by 2028 lacks ambition and fails to address the scale of obesity management need.
• Significant resource gap exists between current provision and clinical demand—wider rollout of GLP-1 receptor agonists would require substantial investment and workforce expansion to implement effectively across primary and secondary care.
• Policy review needed—MPs advocate for more ambitious commissioning targets and clearer funding arrangements to enable equitable access to tirzepatide for eligible obese patients within realistic NHS capacity timelines.

Current plans for 6% of eligible patients to get Mounjaro by 2028 unambitious, say MPs.

ClinicaliQ summarises and contextualises external updates for clinical awareness, then links to the original publisher for the full article and most current context.